Could a simple immunization shield cancer patients from severe COVID-19?

NCT ID NCT04442048

Completed Prevention Sponsor: Canadian Cancer Trials Group Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 trial tested whether a biologic called IMM-101 could reduce severe respiratory infections, including COVID-19, in cancer patients at higher risk. 195 participants either received three doses of IMM-101 or were simply observed. The goal was to see if the treatment could prevent flu-like illness that disrupts cancer care or leads to hospitalization.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: IMM-101 (a biologic vaccine-like agent)
What this could lead to: If it works, this could provide a way to help protect cancer patients from severe respiratory infections, including COVID-19.
What could go wrong: This trial is completed but results are not yet widely reported, so it is unclear if IMM-101 was effective. The study was also relatively small (195 participants), so findings may not apply to all cancer patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer lymphoma neoplasm plasma cell myeloma COVID-19 prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANCER COVID-19

Contacts and locations

Locations

CHUM-Centre Hospitalier de l'Universite de Montreal

Montreal, Quebec, H2X 3E4, Canada
CIUSSS de l'Estrie - Centre hospitalier

Sherbrooke, Quebec, J1H 5N4, Canada
Juravinski Cancer Centre at Hamilton Health Sciences

Hamilton, Ontario, L8V 5C2, Canada
London Regional Cancer Program

London, Ontario, N6A 5W9, Canada
Odette Cancer Centre

Toronto, Ontario, M4N 3M5, Canada
Ottawa Hospital Research Institute

Ottawa, Ontario, K1H 8L6, Canada
The Research Institute of the McGill University

Montreal, Quebec, H4A 3J1, Canada
University Health Network

Toronto, Ontario, M5G 2M9, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.